Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06556563

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Led by NovoCure GmbH · Updated on 2026-05-01

741

Participants Needed

93

Research Sites

216 weeks

Total Duration

On this page

Sponsors

N

NovoCure GmbH

Lead Sponsor

M

Merck Sharp & Dohme LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

CONDITIONS

Official Title

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provided documented informed consent for the study.
  • Age 18 years or older at consent.
  • New diagnosis of Glioblastoma per WHO 2021 Classification.
  • Recovered from maximal debulking surgery; Gliadel wafers placement not allowed.
  • Completed standard chemoradiotherapy including radiotherapy (56-64 Gy) and concomitant Temozolomide.
  • Eligible for treatment with Optune device together with maintenance Temozolomide (150-200 mg/m2 daily for 5 days every 28 days).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 within 7 days before randomization.
  • Stable or decreasing corticosteroid dose (dexamethasone 2 mg or equivalent) for at least 7 days prior to randomization, if applicable.
Not Eligible

You will not qualify if you...

  • Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2 agents or other T-cell receptor targeted agents (e.g., CTLA-4, OX 40, CD137).
  • Ongoing need for more than 2 mg dexamethasone (or equivalent) due to intracranial mass effect.
  • Prior systemic anti-cancer therapy including investigational agents within 4 weeks before randomization.
  • Received live or live-attenuated vaccine within 30 days before first study dose; killed vaccines allowed.
  • Participation in another investigational study or use of an investigational device within 4 weeks prior to first treatment.
  • Diagnosis of immunodeficiency or use of chronic systemic steroids exceeding 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days before first dose.
  • Known additional progressing malignancy requiring active treatment within past 3 years.
  • History of noninfectious pneumonitis/interstitial lung disease requiring steroids or current pneumonitis/interstitial lung disease.
  • Early progressive disease after chemoradiotherapy; if suspected pseudo progression, additional imaging needed.
  • Presence of infratentorial or leptomeningeal disease.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 93 locations

1

Mayo Clinic Hospital

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

University of Southern California

Los Angeles, California, United States, 90033

Actively Recruiting

3

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States, 92663

Actively Recruiting

4

Stanford Cancer Institute

Palo Alto, California, United States, 94305

Actively Recruiting

5

University of California

San Francisco, California, United States, 94143

Actively Recruiting

6

UF Health Neuromedicine

Gainesville, Florida, United States, 32608

Actively Recruiting

7

Mayo Clinic - Florida

Jacksonville, Florida, United States, 32224

Actively Recruiting

8

Miami Cancer Institute

Miami, Florida, United States, 33176

Actively Recruiting

9

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

10

Northwestern Memorial Hospital

Chicago, Illinois, United States, 60611

Actively Recruiting

11

University of Kentucky Medical Center

Lexington, Kentucky, United States, 40536

Actively Recruiting

12

University of Maryland

Baltimore, Maryland, United States, 21201

Actively Recruiting

13

Tufts Medical Center

Boston, Massachusetts, United States, 02111

Actively Recruiting

14

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

15

Mayo Clinic - Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

16

Washington University

St Louis, Missouri, United States, 63110

Actively Recruiting

17

Renown Regional Medical Center

Reno, Nevada, United States, 89502

Actively Recruiting

18

John Theurer Cancer Center/ Hackensack Meridian Health

Hackensack, New Jersey, United States, 07601

Actively Recruiting

19

Northwell Health

Lake Success, New York, United States, 11042

Actively Recruiting

20

Columbia University Irving Medical Center

New York, New York, United States, 10032

Actively Recruiting

21

Montefiore Medical Center- Montefiore Medical Park

The Bronx, New York, United States, 10461

Actively Recruiting

22

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

23

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106

Actively Recruiting

24

The Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

25

Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Clinical Trials Organization

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

26

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

27

Rhode Island Hospital

Providence, Rhode Island, United States, 02903

Actively Recruiting

28

The University of Texas

Houston, Texas, United States, 77030

Actively Recruiting

29

University of Texas, MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

30

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

31

Inova Schar Cancer Institute

Fairfax, Virginia, United States, 22031

Actively Recruiting

32

Swedish Medical Center

Seattle, Washington, United States, 98122

Actively Recruiting

33

The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada, K1H 8L6

Actively Recruiting

34

CHUM

Montreal, Quebec, Canada, H2X 3E4

Actively Recruiting

35

Montreal Neurological Institute-Hospital, Clinical Research Unit

Montreal, Quebec, Canada, H3A 2B4

Actively Recruiting

36

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS)

Sherbrooke, Quebec, Canada, J1H 5N4

Actively Recruiting

37

Nemocnice Na Homolce

Prague, Czechia, 150 30

Actively Recruiting

38

Centre Hospitalier Universitaire de Lyon

Bron, France, 69500

Actively Recruiting

39

Hopital de la Timone

Marseille, France, 13385

Actively Recruiting

40

Hopital Saint-Louis

Paris, France, 75010

Actively Recruiting

41

Groupe Hospitalier Pitie - Salpetriere

Paris, France, 75013

Actively Recruiting

42

Institut Claudius Regaud

Toulouse, France, 31059

Actively Recruiting

43

Charité Campus Virchow-Klinikum

Berlin, Germany, 10117

Actively Recruiting

44

Universitätsklinikum Essen

Essen, Germany, 45147

Actively Recruiting

45

University Hospital Frankfurt

Frankfurt, Germany, 60528

Actively Recruiting

46

Rambam Medical Center

Haifa, Israel, 3109601

Actively Recruiting

47

Rabin Medical Center- Beilinson Hospital

Petah Tikva, Israel, 4941492

Actively Recruiting

48

Chaim Sheba Medical Center

Ramat Gan, Israel, 5265601

Actively Recruiting

49

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel, 64239

Actively Recruiting

50

Neuro-Oncologia Clinica Ospedale Molinette - AOU Città della Salute e della Scienza di Torino

Torino, Torino, Italy, 10126

Actively Recruiting

51

Ospedale Bellaria

Bologna, Italy, 40139

Actively Recruiting

52

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy, 20133

Actively Recruiting

53

Ospedale del Mare

Naples, Italy, 80147

Actively Recruiting

54

UOC Oncologia Medica 1 Istituto Oncologico Veneto IOV-IRCCS

Padova, Italy, 35128

Actively Recruiting

55

IRCCS Istituto Clinico Humanitas

Rozzano, Italy, 20089

Actively Recruiting

56

U.O.C. Immunoterapia Oncologica A.O.U. Senese, Policlinico Santa Maria alle Scotte

Siena, Italy, 53100

Actively Recruiting

57

Tokai University Hospital

Isehara, Kanagawa, Japan, 259-1193

Actively Recruiting

58

Kyushu University Hospital

Fukuoka, Japan, 812-8582

Actively Recruiting

59

Hokkaido University Hospital

Hokkaido, Japan, 060-8648

Actively Recruiting

60

Kanazawa University Hospital

Ishikawa, Japan, 920-8641

Actively Recruiting

61

Kumamoto University Hospital

Kumamoto, Japan, 860-8556

Actively Recruiting

62

Kyoto University Hospital

Kyoto, Japan, 606-8507

Actively Recruiting

63

Kyorin University Hospital

Mitaka, Japan, 181-8611

Actively Recruiting

64

Nagoya University Hospital

Nagoya, Japan, 466-8560

Actively Recruiting

65

Saitama Medical University International Medical Center

Saitama, Japan, 350-1298

Actively Recruiting

66

Tohoku University Hospital

Sendai, Japan, 980-8574

Actively Recruiting

67

National Cancer Center Hospital

Tokyo, Japan, 104-0045

Actively Recruiting

68

Centrum Onkologii

Bydgoszcz, Poland, 85-796

Actively Recruiting

69

Narodowy Instytut Onkologii

Gliwice, Poland, 44-102

Actively Recruiting

70

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika-Zakład Teleradioterapii

Lodz, Poland, 93-513

Actively Recruiting

71

Hospital Universitario Clínico San Carlos

Madrid, Madrid, Spain, 28040

Enrolling by Invitation

72

Hospital Universitario Clínico San Carlos

Madrid, Madrid, Spain, 28040

Actively Recruiting

73

Hospital Universitari Vall d'Hebron

Barcelona, Spain, 08035

Actively Recruiting

74

Institut Català d'Oncologia de L'Hospitalet (ICO L'Hospitalet)

Barcelona, Spain, 08908

Actively Recruiting

75

Hospital Universitario Reina Sofia

Córdoba, Spain, 14004

Actively Recruiting

76

Hospital Universitario Virgen de las Nieves

Granada, Spain, 18014

Actively Recruiting

77

Hospital Universitario Ramón y Cajal

Madrid, Spain, 28034

Actively Recruiting

78

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

79

Hospital Universitario La Paz

Madrid, Spain, 28046

Actively Recruiting

80

Hospital Universitario Virgen del Rocio

Seville, Spain, 41013

Actively Recruiting

81

Hospital Universitari i Politécnic La Fe

Valencia, Spain, 46026

Actively Recruiting

82

University Hospital Basel Medical Oncology

Basel, Switzerland, 4031

Actively Recruiting

83

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Switzerland, 1005

Actively Recruiting

84

University Hospital Zurich

Zurich, Switzerland, 8091

Actively Recruiting

85

Queen Elizabeth

Birmingham, United Kingdom, B15 2TH

Actively Recruiting

86

Addenbrooke's Hospital (Cambridge University Hospitals NHS Foundation Trust)

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

87

Velindre Cancer Centre

Cardiff, United Kingdom, CF14 2TL

Actively Recruiting

88

Western General Hospital

Edinburgh, United Kingdom, EH4 2XU

Actively Recruiting

89

The Clatterbridge Cancer Centre (Clatterbridge Cancer Centre NHS Foundation Trust)

Liverpool, United Kingdom, L7 8YA

Actively Recruiting

90

The Christie Hospital

Manchester, United Kingdom, M20 4BX

Actively Recruiting

91

Weston Park Hospital

Sheffield, United Kingdom, S10 2SJ

Actively Recruiting

92

Southampton General Hospital

Southampton, United Kingdom, SO16 6YD

Actively Recruiting

93

Royal Marsden

Sutton, United Kingdom, SM2 5PT

Actively Recruiting

Loading map...

Research Team

U

Uz Stammberger

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | DecenTrialz